Atezolizumab + cobimetinib in locally advanced or metastatic CRC (Phase III IMblaze370) - primary endpoint analysis
Patients: 360 patients with locally advanced or metastatic CRC >= 2 prior treatments Treatment arms - randomized (2:1:1) to atezolizumab + cobimetinib vs. atezolizumab vs. regorafenib (control) Primary endpoint: OS Results: >95% patients were MSS Combo failed to meet the primary endpoint of OS compared to regorafenib ( https://www.roche.com/media/store/releases/med-cor-2018-05-10.htm ). Safety results were consistent with the known profiles of the individual drugs Roche has halted patient recruitment to cohort 4 (atezolizumab + cobimetinib) in the phase 2 MODUL trial since Apr. 2018 (https://www.biospace.com/article/roche-halts-colorectal-cancer-trial-recruitment-after-4-patient-deaths/)